## Examples of clinically relevant pathogens, required disinfection efficacy and practical recommendations



Helps. Cares. Protects.



| BACTERIA  | Required efficacy  | Practical recommendations   | Additional information  | HARTMANN Products RTU                    | HARTMANN Products concentrates |
|---|--|---|---|--|--------------------------------|
| Bacteria Staphylococcus aureus (MSSA) and other non-drug-resistant staphylococci and enterococci Escherichia coli Klebsiella pneumoniae and other non-drug-resistant Enterobacteriaceae | Standard efficacy<br>(bactericidal<br>EN 13727,<br>yeasticidal<br>EN 13624) <sup>1</sup> | Standard cleaning /<br>disinfection procedure *, **                       | About 30% of people carry MSSA in their noses. Causes nosocomial infections (e. g. wound infections).<br>K. pneumoniae can cause nosocomial pneumonia. Both are mostly transmittet via contact. | Bacillol® 30 Sensitive<br>Tissues / Foam | Mikrobac® forte                |
| Bacteria • Neisseria meningitidis   |  | Disinfection of isolation rooms *** & terminal room disinfection          | Causes bacterial meningitis.<br>Transmission via droplets.<br>Meningococcal vaccines are available<br>against serogroups A, B, C, Y and W.  | Bacillol® AF Bacillol® AF Tissues        |                                |
| Bacteria causing gastroenteritis or respiratory tract infections • Nontyphoidal Salmonella spp., Campylobacter spp. or Shigella spp. • Streptococcus pneumoniae • Bordetella pertussis  |  | Disinfection of isolation rooms *** & terminal room disinfection          | Various animals can be reservoirs for Salmonella (e.g. poultry, pigs, cattle, and reptiles). Streptococcus pneumonia is still a major cause of disease in developing and developed countries.   | Mikrobac® Tissues                        |                                |
| Multidrug-resistant organisms  • Staphylococcus aureus (MRSA)  • Vancomycin-resistant enterococci (VRE)  • Multidrug-resistant Gram-negative bacilli                                    |  | Disinfection of isolation rooms & terminal room disinfection <sup>2</sup> | VRE may persist in the environment.<br>Less therapy options for infections<br>with multidrug-resistance. PPE often<br>reasonable to prevent transmission.                                       | Mikrobac® Virucidal<br>Tissues           | Dismozon® plus                 |



### **MYCOBACTERIA / SPORES**

#### Mycobacteria

Spore-forming bacteria

· Clostridioides difficile

(MDRGNB)

Mycobacterium tuberculosis (MRSA

| ORES | Required efficacy   |  |
|------|---|--|
| 4)   |   |  |
|      | Change to<br>tuberculocidal<br>activity /<br>mycobactericidal |  |
|      | Sporicidal  |  |

(EN 17126)

| Fractical recommendations      |
|--------------------------------|
| Without visible contamination, |
| standard cleaning /            |
| disinfection procedure         |
| may be sufficient *            |

Disinfection of isolation

rooms & terminal room

disinfection 2

nination, Mycobacterium tuberculosis is usually transmitted through air, not by surface contact.

Additional information



**HARTMANN Products RTU** 

Bacillol® 30 Sensitive Bacillol® AF Tissues / Foam Bacillol® AF Tissues





Dismozon® plus

of antibiotics.

Use disinfectants safely. Always read the label and product information before use.



Clostridioides difficile infection is

mostly associated with previous use

<sup>\*</sup> According to risk assessment \*\* Always disinfect high-touch surfaces and visible contamination \*\*\* When isolation precautions are indicated

<sup>1:</sup> Standard efficacy for application in healthcare institutions (bactericidal activity EN 13727, yeasticidal activity EN 13624)

<sup>2:</sup> Consider complementary decontamination (UV-C, H2O2 vaporization) for some species or during outbreaks

SP: Sporicidal activity against C. difficile-spores (EN 17126) Tuberculocidal activity (M. terrae EN 14348, mycobactericidal EN 14348)

PPE: personal protective equipment

# Examples of clinically relevant pathogens, required disinfection efficacy and practical recommendations



|  | FUNGI / YEAST                            | Required efficacy        | Practical recommendations                           | Additional information  | HARTMANN Products RTU                                | HARTMANN Products concentrates |
|--|--|--------------------------|---|---|--|--------------------------------|
|  | Fungi<br>• Aspergillus fumigatus         | Fungicidal               | Standard cleaning /<br>disinfection procedure *, ** | Invasive pulmonary infection may occur in immunosuppressed patients.  | Bacillol® AF<br>Bacillol® AF Tissues                 |                                |
|  |  |                          |   |   | Mikrobac® Virucidal<br>Tissues                       |                                |
|  | Yeast • Candida albicans • Candida auris | Yeasticidal <sup>1</sup> | Standard cleaning /<br>disinfection procedure *, ** | Candida auris has a propensity to cause outbreaks in healthcare facilities.  Often intrinsic resistance to antifungals. | Bacillol® 30 Sensitive<br>Tissues / Foam             | Dismozon® plus                 |
|  |  |                          |   |   | Bacillol® AF Bacillol® AF Tissues  Mikrobac® Tissues |                                |
|  |  |                          |   |   | Mikrobac® Virucidal<br>Tissues                       |                                |



### Examples of clinically relevant pathogens, required disinfection efficacy and practical recommendations



|           | e T |   |
|-----------|-----|---|
| *         |     |   |
| 1         |     |   |
| ج<br>حالت | 4-1 | Ó |
|           | 4   |   |

| VIRUSES  | Required efficacy   | Practical recommendations  | Additional information  | HARTMANN Products RTU  | HARTMANN Products concentrates |
|--|---|--|---|--|--------------------------------|
| Enveloped viruses  • Hepatitis B virus (HBV)  • Human immunodeficiency virus (HIV)  Enveloped viruses causing respiratory tract infections  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  • Respiratory syncytial virus (RSV)  • Influenza viruses (A-C) | Standard efficacy <sup>1</sup> + Virucidal activity against enveloped viruses | Standard cleaning /<br>disinfection procedure *, **<br>Disinfection of isolation rooms<br>& terminal room disinfection | Transmission of SARS-CoV-2 through contact with contaminated fomites is considered possible.  1-2% of children < 6 months with RSV infection may need to be hospitalized.   | Bacillol® 30 Sensitive Bacillol® AF Tissues / Foam Bacillol® AF Tissues  Mikrobac® Mikrobac® Virucidal Tissues | Mikrobac® forte                |
| Non-enveloped viruses causing gastroenteritis  Norovirus  Adenovirus  Non-enveloped viruses causing respiratory tract infections  Adenovirus   | Standard efficacy <sup>1</sup> + Limited spectrum of virucidal activity       | Disinfection of isolation rooms<br>& terminal room disinfection  | Norovirus is very contagious and can spread rapidly throughout healthcare facilities and is often responsible for nosocomial outbreaks.  More than 50 different types of adenoviruses can cause infections in humans e.g. respiratory illness, gastroenteritis, conjunctivitis, and cystitis. | Bacillol® 30 Sensitive Tissues / Foam  Bacillol® AF Bacillol® AF Tissues  Mikrobac®                            | Dismozon® plus                 |



Virucidal Tissues

<sup>\*</sup> According to risk assessment \*\* Always disinfect high-touch surfaces and visible contamination 1: Standard efficacy for application in healthcare institutions (bactericidal activity EN 13727, yeasticidal activity EN 13624) envV: Virucidal activity against enveloped viruses (EN 14776)

Isv: Limited spectrum virucidal activity (EN 14476)

V: Virucidal activity (EN 14476)